Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thromboxane biosynthesis in cardiovascular diseases.

C Patrono1, G Ciabattoni, G Davi

  • 1Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.

Stroke
|December 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RENEB Inter-Laboratory Comparison 2021: Inter-Assay Comparison of Eight Dosimetry Assays.

Radiation research·2023
Same author

RENEB Inter-Laboratory Comparison 2021: The Cytokinesis-Block Micronucleus Assay.

Radiation research·2023
Same author

RENEB Inter-Laboratory Comparison 2021: The Dicentric Chromosome Assay.

Radiation research·2023
Same author

A NOVEL BIOLOGICAL DOSIMETRY ASSAY AS A POTENTIAL TOOL FOR TRIAGE DOSE ASSESSMENT IN CASE OF LARGE-SCALE RADIOLOGICAL EMERGENCY.

Radiation protection dosimetry·2019
Same author

Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now.

Clinical pharmacology and therapeutics·2017
Same author

In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease.

Clinical pharmacology and therapeutics·2017

Sudden plaque fissuring can cause transient ischemia, with enhanced thromboxane A2 (TXA2) biosynthesis contributing to platelet activation. Aspirin therapy effectively reduces thrombotic events in conditions like unstable angina and myocardial infarction.

Area of Science:

  • Cardiovascular Medicine
  • Thrombosis and Hemostasis
  • Pharmacology

Background:

  • Atherosclerotic plaque fissuring is a proposed trigger for transient ischemic events in coronary and cerebral circulation.
  • Enhanced thromboxane A2 (TXA2) biosynthesis is implicated in platelet activation at acute vascular lesions, evidenced by metabolite excretion in unstable angina.
  • Aspirin (75-325 mg/day) reduces thrombotic events in unstable angina and acute myocardial infarction, suggesting a role for TXA2 in these conditions.

Purpose of the Study:

  • To investigate the role of thromboxane A2 (TXA2) in acute vascular events and metabolic abnormalities.
  • To evaluate the impact of Aspirin therapy on TXA2-mediated platelet activation and thrombotic risk.
  • To explore the potential of low-dose Aspirin and TXA2-receptor antagonists in managing metabolic conditions with high thrombotic risk.

Related Experiment Videos

Main Methods:

  • Measurement of urinary 11-dehydro-TXB2 and 2,3-dinor-TXB2 metabolites.
  • Analysis of Aspirin trial data (e.g., ISIS-2).
  • Assessment of TXA2 biosynthesis and platelet function in conditions like unstable angina, myocardial infarction, percutaneous transluminal coronary angioplasty, diabetes mellitus, and hypercholesterolemia.

Main Results:

  • Episodic increases in TXA2 metabolite excretion are observed in unstable angina and during percutaneous transluminal coronary angioplasty.
  • Short-term Aspirin therapy shows significant impact on thrombotic events in acute myocardial infarction.
  • Non-insulin-dependent diabetes mellitus and type IIa hypercholesterolemia exhibit persistent TXA2-dependent platelet abnormalities, responsive to low-dose Aspirin (50 mg/day).

Conclusions:

  • TXA2-mediated platelet activation plays a significant role in both acute vascular events and chronic metabolic abnormalities.
  • Aspirin therapy is effective in mitigating TXA2-driven thrombotic complications.
  • Low-dose Aspirin and selective TXA2-receptor antagonists warrant further investigation for managing thrombotic risk in diabetes and hypercholesterolemia.